| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | HER2 Protein Overexpression, mRNA Expression, and DNA Amplification Across Solid Tumors: Comparison of Next-Generation Sequencing-Based Assays With Immunohistochemistry. |
| 掲載誌名 | 正式名：JCO precision oncology 略 称：JCO Precis Oncol ISSNコード：24734284/24734284 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 10,pp.e2500413 |
| 著者・共著者 | Michiko Nagamine, Takao Fujisawa, Naoya Sakamoto, Yoshiaki Nakamura, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Yoshito Komatsu, Eiji Oki, Akitaka Makiyama, Norio Nonomura, Chigusa Morizane, Hidemichi Watari, Susumu Okano, Hiroji Iwata, Kenjiro Namikawa, Yutaka Hatanaka, Kanako C Hatanaka, Kenichi Taguchi, David Spetzler, Milan Radovich, Daniel Magee, Takayuki Yoshino, Matthew Oberley, Takeshi Kuwata |
| 発行年月 | 2026/01 |
| 概要 | PURPOSE:The tumor-agnostic approach has been increasingly adopted in precision oncology. Immunohistochemistry (IHC) is the standard biomarker testing for human epidermal growth factor receptor 2 (HER2)-targeted therapies, whereas next-generation sequencing (NGS) has been widely incorporated in routine clinical practices. Here, we investigated the concordance between NGS-based assays and IHC in HER2 testing. Interfering factors leading to discordant results between the assays were also studied.MATERIALS AND METHODS:Over 78,000 solid tumors across various types from two independent cohorts in the United States and Japan were investigated for HER2 DNA copy number, mRNA expression, and protein overexpression by whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), and IHC, respectively.RESULTS:In the US cohort (n = 77,267), HER2 DNA amplification, mRNA overexpression, and IHC-positive (IHC-P) were detected in 4.9%, 10.1%, and 4.7% of the tumors, respectively. Positive results in at least one of the three assays were observed in 10.7% of tumors, while 3.9% were positive for all three assays. Using IHC as a comparator, WTS showed better sensitivity than WES but a lower positive predictive value. These results were consistent in the Japanese cohort (n = 1,225). Although the overall HER2 RNA expression level correlated well with IHC score and DNA copy number, the degree of correlation varied among tumor types. Heterogeneous distribution of IHC-P tumor cells was associated with discordant results between NGS-based assays and IHC.CONCLUSION:HER2-positive status in protein, mRNA, and DNA showed concordance in general but varied among tumor types. NGS-based assays, especially WTS, could be a useful predictive tool for HER2 testing in tumor-agnostic settings. Intratumor heterogeneity in HER2 protein expression should be considered when bringing bulk sequencing tests into clinical settings. |
| DOI | 10.1200/PO-25-00413 |
| PMID | 41564373 |